Palermo M, Tomasi P A, Delitala G
Cattedra di Endocrinologia, Università degli Studi di Sassari.
Ann Ital Med Int. 1991 Oct-Dec;6(4):364-8.
The effects of two calcium channel blockers nifedipine (20 mg sublingual), and verapamil (10 mg i.v.) on growth hormone (GH), thyrotropin (TSH), prolactin (PRL) and gonadotropin (LH and FSH) secretion induced by growth hormone releasing hormone (GHRH), hypoglycemia, thyrotropin releasing hormone (TRH), metoclopramide and gonadotropin releasing hormone (GnRH), were studied in a group of normal volunteers (27 men and 8 women). Neither nifedipine nor verapamil had any effect on PRL, TSH or gonadotropin release. Verapamil did not cause variations in GH secretion following GHRH and insulin-induced hypoglycemia, whereas nifedipine significantly reduced the elevation in GH induced by GHRH; however the GHRH-mediated GH rise still remained within the normal range in all subjects. Our results suggest that neither nifedipine nor verapamil have important effects on stimulated pituitary hormone secretion, at least under conditions of acute administration.
在一组正常志愿者（27名男性和8名女性）中，研究了两种钙通道阻滞剂硝苯地平（舌下含服20毫克）和维拉帕米（静脉注射10毫克）对生长激素释放激素（GHRH）、低血糖、促甲状腺激素释放激素（TRH）、胃复安和促性腺激素释放激素（GnRH）诱导的生长激素（GH）、促甲状腺激素（TSH）、催乳素（PRL）和促性腺激素（LH和FSH）分泌的影响。硝苯地平和维拉帕米对PRL、TSH或促性腺激素释放均无任何影响。维拉帕米不会引起GHRH和胰岛素诱导的低血糖后GH分泌的变化，而硝苯地平显著降低了GHRH诱导的GH升高；然而，在所有受试者中，GHRH介导的GH升高仍保持在正常范围内。我们的结果表明，至少在急性给药条件下，硝苯地平和维拉帕米对刺激的垂体激素分泌均无重要影响。
